The Rwanda Food and Drugs Authority (Rwanda FDA) has announced the immediate suspension of the importation, distribution, and use of all RELIEF tablets until further notice. In a public statement issued on June 11, the FDA revealed that post-marketing surveillance had detected unauthorized medicines branded as RELIEF on the Rwandan market. These tablets, available in various dosages, contain a combination of Diclofenac Sodium, Paracetamol, Chlorpheniramine Maleate, and Magnesium Trisilicate. ALSO READ: Rwanda recalls French-manufactured aspirin over quality concerns “All importers, distributors, and retail pharmacies are required to immediately cease the distribution and dispensing of RELIEF tablets and quarantine all existing stock,” the statement reads. Rwanda FDA strongly advises the public against purchasing or using any RELIEF tablets, emphasizing that the use of unauthorized medicines poses serious health risks. ALSO READ: How and when does Rwanda FDA recall pharmaceutical products? The authority further reminded stakeholders that the importation, distribution, or dispensing of unapproved medicines is illegal and punishable by law.
